Denali Therapeutics (DNLI) Cash & Equivalents (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Cash & Equivalents data on file, last reported at $387.6 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 580.68% year-over-year to $387.6 million in Q1 2026; TTM through Mar 2026 was $387.6 million, a 580.68% increase from a year earlier, with the FY2025 full-year figure at $205.3 million, up 17.36% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $387.6 million, up from $205.3 million in the prior quarter.
• Over the last five years, Cash & Equivalents for DNLI reached as high as $387.6 million in Q1 2026 and fell as low as $56.9 million in Q1 2025.
• Historically, Cash & Equivalents has averaged $138.5 million across 5 years, with a median of $127.1 million in 2023.
• Across the five-year window, Cash & Equivalents slumped 75.89% in 2022 and surged 580.68% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $218.0 million in 2022, then plunged by 41.71% to $127.1 million in 2023, then jumped by 37.65% to $175.0 million in 2024, then gained by 17.36% to $205.3 million in 2025, then soared by 88.79% to $387.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $387.6 million in Q1 2026, $205.3 million in Q4 2025, and $91.0 million in Q3 2025.